Cargando…

Platelets in Non-alcoholic Fatty Liver Disease

Non alcoholic steatohepatitis (NASH) is the inflammatory reaction of the liver to excessive accumulation of lipids in the hepatocytes. NASH can progress to cirrhosis and hepatocellular carcinoma (HCC). Fatty liver is the hepatic manifestation of metabolic syndrome. A subclinical inflammatory state i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalbeni, Andrea, Castelli, Marco, Zoncapè, Mirko, Minuz, Pietro, Sacerdoti, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895200/ https://www.ncbi.nlm.nih.gov/pubmed/35250588 http://dx.doi.org/10.3389/fphar.2022.842636

Ejemplares similares

Metabolic-associated fatty liver disease and liver fibrosis scores as COVID-19 outcome predictors: a machine-learning application
por: Zoncapè, Mirko, et al.
Publicado: (2023)

Multi-disciplinary clinic models for the management of non-alcoholic fatty liver disease
por: Zoncapè, Mirko, et al.
Publicado: (2022)

Platelet-Derived Extracellular Vesicles as Target of Antiplatelet Agents. What Is the Evidence?
por: Taus, Francesco, et al.
Publicado: (2019)

Metabolic dysfunction-associated fatty liver disease and liver fibrosis score in patients with COVID-19 as predictors of adverse clinical outcomes: an artificial intelligent application through machine learning
por: Dalbeni, A., et al.
Publicado: (2022)

Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
por: Fu, Yajie, et al.
Publicado: (2022)

The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
por: Yu, Siyu, et al.
Publicado: (2021)

Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population
por: Dalbeni, Andrea, et al.
Publicado: (2023)

Antiplatelet Agents Inhibit the Generation of Platelet-Derived Microparticles
por: Giacomazzi, Alice, et al.
Publicado: (2016)

Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?
por: Chandrasekharan, Karthik, et al.
Publicado: (2020)

The protective roles of augmenter of liver regeneration in hepatocytes in the non-alcoholic fatty liver disease
por: Dong, Yuan, et al.
Publicado: (2022)

Natural flavonoids: Potential therapeutic strategies for non-alcoholic fatty liver disease
por: Tan, Panli, et al.
Publicado: (2022)

Editorial: Natural products as potential therapies for non-alcoholic fatty liver disease
por: Ibrahim, Islam A. A. E. H., et al.
Publicado: (2023)

Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes
por: Mantovani, Alessandro, et al.
Publicado: (2022)

Identifying Candidate Flavonoids for Non-Alcoholic Fatty Liver Disease by Network-Based Strategy
por: Lee, Won-Yung, et al.
Publicado: (2022)

Analysis of the correlation between non-alcoholic fatty liver disease and the risk of colorectal neoplasms
por: Ye, Shujun, et al.
Publicado: (2022)

Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets
por: Blas-García, Ana, et al.
Publicado: (2022)

A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease
por: Rieger, Theodore R., et al.
Publicado: (2022)

Lipophagy and Alcohol-Induced Fatty Liver
por: Yang, Li, et al.
Publicado: (2019)

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment
por: Yu, Lili, et al.
Publicado: (2022)

Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine
por: Shao, Mingmei, et al.
Publicado: (2022)

Multi-Omics Reveals Inhibitory Effect of Baicalein on Non-Alcoholic Fatty Liver Disease in Mice
por: Li, Ping, et al.
Publicado: (2022)

Hepatoprotective Effect and Molecular Mechanisms of Hengshun Aromatic Vinegar on Non-Alcoholic Fatty Liver Disease
por: Zhu, Shenghu, et al.
Publicado: (2020)

Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease
por: Xu, Jingqi, et al.
Publicado: (2021)

The essential effect of mTORC1-dependent lipophagy in non-alcoholic fatty liver disease
por: Tan, Xiangyun, et al.
Publicado: (2023)

LncRNA-AK012226 Is Involved in Fat Accumulation in db/db Mice Fatty Liver and Non-alcoholic Fatty Liver Disease Cell Model
por: Chen, Xingtian, et al.
Publicado: (2018)

Aurantio-Obtusin Attenuates Non-Alcoholic Fatty Liver Disease Through AMPK-Mediated Autophagy and Fatty Acid Oxidation Pathways
por: Zhou, Fei, et al.
Publicado: (2022)

Calcium-Dependent Src Phosphorylation and Reactive Oxygen Species Generation Are Implicated in the Activation of Human Platelet Induced by Thromboxane A2 Analogs
por: Minuz, Pietro, et al.
Publicado: (2018)

Mendelian Randomization Rules Out Causation Between Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease
por: Chen, Lanlan, et al.
Publicado: (2022)

Gentiana scabra Restrains Hepatic Pro-Inflammatory Macrophages to Ameliorate Non-Alcoholic Fatty Liver Disease
por: Zheng, Yiyuan, et al.
Publicado: (2022)

Elevated Serum Regulator of Calcineurin 2 is Associated With an Increased Risk of Non-Alcoholic Fatty Liver Disease
por: Fang, Xia, et al.
Publicado: (2022)

Herbal Extracts and Natural Products in Alleviating Non-alcoholic Fatty Liver Disease via Activating Autophagy
por: Zhang, Li, et al.
Publicado: (2018)

Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application
por: Xu, Yu, et al.
Publicado: (2020)

Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System
por: Yang, Mengying, et al.
Publicado: (2020)

Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice
por: Wu, Jingyi, et al.
Publicado: (2023)

Erratum: Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice
por: Frontiers Production Office,
Publicado: (2023)

Limonin Alleviates Non-alcoholic Fatty Liver Disease by Reducing Lipid Accumulation, Suppressing Inflammation and Oxidative Stress
por: Li, Yunjia, et al.
Publicado: (2022)

Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy
por: Mertens, Jonathan, et al.
Publicado: (2021)

Naringenin Attenuates Non-Alcoholic Fatty Liver Disease by Enhancing Energy Expenditure and Regulating Autophagy via AMPK
por: Yang, Ying, et al.
Publicado: (2021)

Network Pharmacology-Based Analysis on the Potential Biological Mechanisms of Sinisan Against Non-Alcoholic Fatty Liver Disease
por: Wei, Xiaoyi, et al.
Publicado: (2021)

Coffee Consumption and Non-alcoholic Fatty Liver Disease: An Umbrella Review and a Systematic Review and Meta-analysis
por: Kositamongkol, Chayanis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3el7l1kjo72p9231djdvuqaod5